Expression and export of angiogenesis inhibitors as immunofusins
CA 2339331 C · Owner: Gillies, Stephen D. · Inventors: Lo, Kin-Ming; Gillies, Stephen D.; Li, Yue
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are nucleotide sequences, for example DNA or RNA sequences, which , encode an immunoglobulin Fc-angiogenesis inhibitor fusion protein. The angiogenesis inhibitors can be angiostatin endostatin, a plasminogen fragment having angiostatin activity or a collagen XVIII fragment having endostatin activity. The nucleotide sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fcangiogenesis inhibitor fusion proteins that can be produced by expression of such nucleotide sequences. Also disclosed are methods using such nucleotide sequences and fusion proteins for treating conditions mediated by …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 1999 and granted March 1, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.